XTANDI: the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in non-metastatic hormone-sensitive prostate cancer (nmHSPC) with high-risk biochemical ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Cardiac Substructure Radiation Dose and Risk of Late Cardiac Disease in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study Eligible participants had mCRPC that progressed ...
The advent of more effective treatment combinations for metastatic hormone-sensitive prostate cancer (mHSPC) has been built on successes in therapy development for metastatic, castration-resistant ...
Major advances have been made in the use of immunotherapy for the treatment of solid tumours, including the use of intratumourally injected immunotherapy instead of systemically delivered ...
The phase 3 ARASTEP trial will investigate Nubeqa plus androgen-deprivation therapy in certain patients with hormone-sensitive prostate cancer. Researchers are looking to enroll approximately 750 ...
A partitioned-survival lifetime model (2025 USD) compared ADT alone with seven intensification strategies across PFS, post-progression, and death, using published survival curves and literature-based ...
NPR's Ayesha Rascoe talks with urologist Ben Davies about the prevalence of prostate cancer, new treatments, and patients' reluctance to discuss the disease and its aftermath. Early last week, after ...
First PARP inhibitor + ARPI combination to show consistent rPFS improvement in HRR gene‑altered metastatic hormone‑sensitive prostate cancer, including both BRCA and non‑BRCA alterations There was an ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results